Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alseres Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: GREATMOOD who wrote (551)	3/11/1998 6:35:00 PM
From: JMarcus	Read Replies (1) \| Respond to of 975

With 12.72 million shares outstanding and $1.27 per share in cash (http://cbs.marketwatch.com/http2_data/squote.htx?source=htx%2Fhttp2_mw&ticker=blsi&tables=market&format=fractions), the Street is only valuing this company's pipeline at $.73 per share at the current $2 per share stock price. Does this low valuation make any sense? I don't think so. The company says it will apply for an NDA for Therafectin within a few weeks. News of that filing, when it occurs, will cause this stock to soar. At $2 per share against $1.27 in cash, I see minimal downside risk and huge upside potential.